Association between Mismatch Repair Gene MSH3 codons 1036 and 222 Polymorphisms and Sporadic Prostate Cancer in the Iranian Population

  • Jafary, Fariba (Young Researcher Club. I.A.U. Falavarjan University) ;
  • Salehi, Mansoor (Division of Genetics, Department of Biomedical Sciences, Isfahan University of Medical Sciences) ;
  • Sedghi, Maryam (Medical Genetics Laboratory, Alzahra Hospital. Medical University of Medical Sciences) ;
  • Nouri, Nayereh (Medical Genetics Laboratory, Alzahra Hospital. Medical University of Medical Sciences) ;
  • Jafary, Farzaneh (Biology Department, Faculty of Basic Science, Alzahra Univercity) ;
  • Sadeghi, Farzaneh (Department of Anatomical Sciences, Medical School, Isfahan University of Medical Sciences) ;
  • Motamedi, Shima (School of Veterinary Medicine, Razi University) ;
  • Talebi, Maede (Young Researcher Club. I.A.U. Falavarjan University)
  • Published : 2012.12.31


The mismatch repair system (MMR) is a post-replicative DNA repair mechanism whose defects can lead to cancer. The MSH3 protein is an essential component of the system. We postulated that MSH3 gene polymorphisms might therefore be associated with prostate cancer (PC). We studied MSH3 codon 222 and MSH3 codon 1036 polymorphisms in a group of Iranian sporadic PC patients. A total of 60 controls and 18 patients were assessed using the polymerase chain reaction and single strand conformational polymorphism. For comparing the genotype frequencies of patients and controls the chi-square test was applied. The obtained result indicated that there was significantly association between G/A genotype of MSH3 codon 222 and G/G genotype of MSH3 codon 1036 with an increased PC risk (P=0.012 and P=0.02 respectively). Our results demonstrated that MSH3 codon 222 and MSH3 codon 1036 polymorphisms may be risk factors for sporadic prostate cancer in the Iranian population.


Sporadic prostate cancer;polymorphism;DNA mismatch repair;MSH3;Iran


  1. Jens P, Stefan K, Birgit J, et al (2004). Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res, 64, 864-70.
  2. John MH, Mark M (1999). MSH3 deficiency is not sufficient for a mutator phenotype in Chinese hamster ovary cells. Carcinogenesis, 20, 215-20.
  3. Kenji F (2012). DNA mismatch repair in eukaryotes and bacteria. J Nucleic Acids, 679, 5148.
  4. Liang W, Shannon KM, Scott JH, et al (2008). Polymorphisms in mitochondrial genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 17, 3558-66.
  5. Mathonnet G, MajaK, Damian L, et al (2003). Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemi. Br J Haemat, 123, 45-8.
  6. Maurice PZ, Humera SK, Leo JS, et al (2011). Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. Eur J Hum Genet, 19, 118-20.
  7. Orimo H, Nakajima E, Yamamoto M, et al (2000). Association between single nucleotid polymorphism in the hmsh3 gene and sporadic colon cancer with microsatellite instability. J Hum Genet, 45, 228-30.
  8. Paivi P (2001). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet, 10, 735-40.
  9. Risinger JI, Umar A, Boyd J, et al (1996). Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat Genet, 14, 102-5.
  10. Sanguinetti CJ, Dias NE, Simpson AJ (1994). Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques, 17, 914-21.
  11. Shukla S, Gupta S (2005). Dietary agents in the chemoprevention of prostate cancer. Nutrcancer, 53, 18.
  12. Song H, Ramus SJ, Quaye L, et al (2006). Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis, 27, 2235-42.
  13. Sonja I, Berndt L, Elizabeth AP, et al (2007). Mismatch repair polymorphisms and the risk of colorectal cancer. Int J Cancer, 120, 1548-54.
  14. Sung-Hoon J, Tae GK, Changill B (2006). DNA mismatches repair system Classical and fresh roles. FEBS J, 273, 1609-19.
  15. Thomas AK, Dorothy A (2005). DNA mismatch repair. Annu Rev Biochem, 74, 681-710.
  16. Walter HL, Julie EC, Jerzy M, et al (2011). Conformational trapping of mismatch recognition complex MSH2/MSH3 on repair-resistant DNA loops. PNAS, 108, 837-44.
  17. Wei Y (2000). Structure and function of mismatch repair proteins. Mutat Res, 460, 245-56.
  18. Winfried E, Asad U, Kan Y, et al (2000). The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res, 60, 803-7.
  19. Xiaoqun D, Yanan L, Kenneth RH, et al (2011). DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist, 16, 61-70.
  20. Angie S, Luke DR, Ginny LE, et al (2005). CYP3A43 Pro (340) ala polymorphism and prostate cancer risk in african americans and caucasians. Cancer Epidemiol Biomarkers Prev, 14, 1257-61.
  21. Brian DH, Sue JR (2000). DNA mismatches repair and genetic instability. Annu Rev Genet, 34, 359-99.
  22. Crawford ED (2003). Epidemiology of prostate cancer. Urology, 62, 10-3.
  23. Ebru K, Arzu E, Fehmi N, et al (2009). ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population. Anticancer Res, 29, 1395-8.
  24. Erika MK, Claudia AS, Suzanne K, et al (2011). Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 20, 923-33.
  25. Hiroshi H, Yuji H, Ken K, et al (2008). Mismatch repair gene MSH3 polymorphisms associated with the risk of sporadic prostate cancer. J Urology, 179, 2020-4.
  26. Huixian W, John B (2007). Human DNA mismatch repair: coupling of mismatch recognition to strand-specific excision. Nucleic Acids Res, 35, 6727-39.
  27. Iyer RR, Pluciennik A, Burdett V, et al (2006). DNA mismatch repair: functions and mechanisms. Chem Rev, 106, 302-23.

Cited by

  1. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome vol.16, pp.1, 2016,
  2. Inactivation of MSH3 by promoter methylation correlates with primary tumor stage in nasopharyngeal carcinoma vol.40, pp.3, 2017,